Endoscopic sleeve gastroplasty (ESG) has emerged as a promising non-surgical alternative for weight loss and liver health improvement, significantly outperforming sham endoscopy in reducing body weight (–9.47% vs. –3.91%) and improving liver stiffness and steatosis. While ESG effectively enhanced NAFLD activity scores, its impact on fibrosis stages remained modest. Despite minor adverse events requiring brief hospitalization, ESG demonstrated a favorable safety profile. Positioned as a second-line treatment for metabolic dysfunction-associated steatohepatitis (MASH) and obesity, ESG shows potential, especially for patients unresponsive to lifestyle changes. Could this be the breakthrough for non-invasive management of complex metabolic conditions?
Trending
- AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma (Los Angeles Times)
- BE Surveillance, Outpatient ESD, and More (GI & Endoscopy News)
- HHS-OIG Issues Favorable Advisory Opinion for Free Multi-Cancer Detection Supplemental Reports Provided with Medicare-Covered Colorectal Cancer Screening Tests (The National Law Review)
- Physician–researcher’s work yields landmark five-year data for Crohn’s disease drug (Medical Xpress)
- CU Anschutz Biobank Partners with Tech Company to Advance Gut Research and Patient Care (The Regents of the University of Colorado)
- Novant Health adds leading gastroenterology clinicians to its Lowcountry network (Novant Health)
- Solutions Emerging for Post-GLP-1 Weight Regain (Medscape)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening (Business Wire)
